MedTrace Logo

Clinical Prognosis and Progression of Myasthenia Gravis Patients

NCT04101578 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2021-08-23

No results posted yet for this study

Summary

This study collects the clinical data of myasthenia gravis (MG) patients, assesses outcomes and adverse effects of different treatment regimens, and searches for risk factors of conversion to generalized MG.

Conditions

Interventions

DRUG

Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg)

Treatment regimens are determined according to the physician's judgment and preferences of the patients.

Sponsors & Collaborators

  • Da, Yuwei, M.D.

    lead INDIV

Principal Investigators

  • yuwei Da, M.D. · Xuan Wu Hospital, Capital Medical University

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-08
Primary Completion
2023-06-01
Completion
2024-12-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04101578 on ClinicalTrials.gov